Table 2.
Study population in the tumor necrosis factor–related weak inducer of apoptosis (TWEAK) cohort.
| Parameter | |
|---|---|
| Number | 134 |
| Sex (male/female) | 76/58 (56.7/43.3%) |
| Age median (range) (years) | 67.50 (26–84) |
| Tumor type | |
| IPMN | 8 (6%) |
| PanIN | 10 (7.5%) |
| PDAC | 116 (86.6%) |
| Staging | |
| T1–T2–T3–T4 | 2–3–66–8 (1.5–2.2–49.3–6%) |
| N0–N1 | 23–52 (17.2–38.9%) |
| M0–M1 | 88–36 (65.7–26.9%) |
| G2–G3 | 43–33 (32.1–24.6%) |
| R0–R1–R2 | 42–19–3 (31.3–14.2–2.2%) |
| UICC | |
| I–II–III–IV | 4–64–4–36 (3–47.8–3–26.9%) |
| ECOG | |
| ECOG 0 | 60 (44.8%) |
| ECOG I | 44 (32.8%) |
| ECOG II | 39 (29.1%) |
| ECOG III | 6 (4.5%) |
| ECOG IV | 1 (0.7%) |
| Fatigue | |
| None | 45 (33.6%) |
| Low | 19 (14.1%) |
| Medium | 17 (12.7%) |
| High | 21 (15.7%) |
| Pain scale | |
| 0 | 64 (47.8%) |
| 1–4 | 12 (9%) |
| 5–7 | 20 (14.9%) |
| 8–10 | 6 (4.5%) |
| CRP median (range) (mg/L) | 7.75 (0–237) |
| Bilirubin median (range) (mg/dL) | 0.57 (0.15–26.20) |
| GGT median (range) (U/L) | 107 (10–2138) |
| AP median (range) (U/L) | 125.5 (39–1574) |
| AST median (range) (U/L) | 27 (13–418) |
| ALT median (range) (U/L) | 35 (7–569) |
| CEA median (range) (µg/L) | 3 (0.22–76.30) |
| CA 19-9 median (range) (kU/L) | 86.15 (0.6–266,567) |
| Creatinine median (range) (mg/dL) | 0.82 (0.4–53.0) |
| WBC median (range) (cells/µL) | 7.4 (2.7–23.30) |
CRP, C-reactive protein; WBC, white blood cell count; AST, aspartate transaminase; ALT alanine transaminase; GGT, γ-glutamyl-transpeptidase; AP, alkaline phosphatase; CEA, carcinoembryonic antigen; CA 19-9 carbohydrate antigen.